Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners


Other names: Celcuity LLC | Celcuity LLC. | Celcuity Inc. | Celcuity Inc | Celcuity | Celcuity, Inc. | Celcuity, Inc | CELCUITY | Celcuity, LLC | Celcuity, LLC.
Related tests:


Celcuity Announces Clinical Trial Collaboration with University of Rochester Wilmot Cancer Center and Puma to Study Patients with Breast Cancer Brain Metastases (Businesswire)
"Celcuity...announced a clinical trial collaboration with the University of Rochester Wilmot Cancer Center and Puma Biotechnology...to conduct a Phase 2 clinical trial....Study will evaluate the efficacy and safety of NERLYNX® plus XELODA® in patients selected by the CELsignia® Test who have metastatic HER2-negative breast cancer with brain metastases...Celcuity expects to obtain interim results 12 to 15 months after initiation of the trial followed by the final results 12 to 15 months later. Celcuity expects enrollment to begin by early to mid-2022."
Licensing / partnership • P2 data • Enrollment status • New P2 trial
CELsignia test
Nerlynx (neratinib) • capecitabine